McClellan: post-market data best for gauging new technology in US
This article was originally published in Clinica
Executive Summary
Medicare's top administrator, Mark McClellan, is promising to play a greater role in encouraging post-market studies, believing these are less costly and more useful than the data available from the hot-house world of the clinical trial.